Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Nov 13;72(20):2471-2481.
doi: 10.1016/j.jacc.2018.08.2181.

Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations

Fernando Domínguez  1 , Sofía Cuenca  2 , Zofia Bilińska  3 , Rocío Toro  4 , Eric Villard  5 , Roberto Barriales-Villa  6 , Juan Pablo Ochoa  7 , Folkert Asselbergs  8 , Arjan Sammani  9 , Maria Franaszczyk  10 , Mohammed Akhtar  11 , Maria José Coronado-Albi  12 , Diego Rangel-Sousa  13 , Jose F Rodriguez-Palomares  14 , Juan Jiménez-Jáimez  15 , José Manuel Garcia-Pinilla  16 , Tomás Ripoll-Vera  17 , Maria Victoria Mogollón-Jiménez  18 , Ana Fontalba-Romero  19 , Dolores Garcia-Medina  20 , Julian Palomino-Doza  21 , David de Gonzalo-Calvo  22 , Marcos Cicerchia  23 , Joel Salazar-Mendiguchia  23 , Clara Salas  24 , Sabine Pankuweit  25 , Thomas Morris Hey  26 , Jens Mogensen  26 , Paul J Barton  27 , Philippe Charron  5 , Perry Elliott  11 , Pablo Garcia-Pavia  28 ; European Genetic Cardiomyopathies Initiative Investigators
Collaborators, Affiliations
Multicenter Study

Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations

Fernando Domínguez et al. J Am Coll Cardiol. .

Abstract

Background: The BAG3 (BLC2-associated athanogene 3) gene codes for an antiapoptotic protein located on the sarcomere Z-disc. Mutations in BAG3 are associated with dilated cardiomyopathy (DCM), but only a small number of cases have been reported to date, and the natural history of BAG3 cardiomyopathy is poorly understood.

Objectives: This study sought to describe the phenotype and prognosis of BAG3 mutations in a large multicenter DCM cohort.

Methods: The study cohort comprised 129 individuals with a BAG3 mutation (62% males, 35.1 ± 15.0 years of age) followed at 18 European centers. Localization of BAG3 in cardiac tissue was analyzed in patients with truncating BAG3 mutations using immunohistochemistry.

Results: At first evaluation, 57.4% of patients had DCM. After a median follow-up of 38 months (interquartile range: 7 to 95 months), 68.4% of patients had DCM and 26.1% who were initially phenotype-negative developed DCM. Disease penetrance in individuals >40 years of age was 80% at last evaluation, and there was a trend towards an earlier onset of DCM in men (age 34.6 ± 13.2 years vs. 40.7 ± 12.2 years; p = 0.053). The incidence of adverse cardiac events (death, left ventricular assist device, heart transplantation, and sustained ventricular arrhythmia) was 5.1% per year among individuals with DCM. Male sex, decreased left ventricular ejection fraction. and increased left ventricular end-diastolic diameter were associated with adverse cardiac events. Myocardial tissue from patients with a BAG3 mutation showed myofibril disarray and a relocation of BAG3 protein in the sarcomeric Z-disc.

Conclusions: DCM caused by mutations in BAG3 is characterized by high penetrance in carriers >40 years of age and a high risk of progressive heart failure. Male sex, decreased left ventricular ejection fraction, and enlarged left ventricular end-diastolic diameter are associated with adverse outcomes in patients with BAG3 mutations.

Keywords: BAG3; dilated cardiomyopathy; genetics; prognosis.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Flowchart of Patients Included in the Study *1 patient was still on LVAD at last evaluation. BAG3 = BLC2-associated athanogene 3; DCM = dilated cardiomyopathy; FU = follow-up; HF = heart failure; HTx = heart transplantation; IQR = interquartile range; LVAD = left ventricular assist device; SCD = sudden cardiac death.
Figure 2
Figure 2
Clinical Events During Follow-Up of Individuals With BAG3 Mutation SVT/FV = sustained ventricular tachycardia/ventricular fibrillation; other abbreviations as in Figure 1.
Figure 3
Figure 3
Survival Analysis in BAG3 DCM (A) Global survival free of the primary composite endpoint (heart transplantation, left ventricular assist device, cardiac death, aborted SCD and appropriate ICD shock). Analysis from date of first evaluation until last follow-up or event. (B) Male sex as risk factor for clinical events. ICD = implantable cardioverter-defibrillator; other abbreviations as in Figure 1.
Central Illustration
Central Illustration
Clinical Outlook and Outcomes of 129 Patients With BAG3 Mutations BAG3 = BLC2-associated athanogene 3; DCM = dilated cardiomyopathy; ECG = electrocardiogram; HF = heart failure; ICD = implantable cardioverter defibrillator; LVAD = left ventricular assist device; SCD = sudden cardiac death; SVT = sustained ventricular tachycardia.
Figure 4
Figure 4
BAG3 Localization in Explanted Hearts Samples fluorescently labeled for actinin (green) and BAG3 (red). Scale bar: 50 μm. (Left column) The first row belongs to a patient without mutations. The second row to a patient with a mutation in Lamin, and the third and fourth rows to patients with truncating mutations in TTN. Samples labeled with actinin and BAG3 show normal localization of the proteins on Z-discs on all the patients. (Right column) The first row belongs to a patient without mutations. Subsequent rows belong to patients with BAG3 truncating mutations. In patients with BAG3 mutations, BAG3 is present at Z-discs but appears disorganized. Myofibrillar disarray can also be observed. BAG3 = BLC2-associated athanogene 3.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Japp A.G., Gulati A., Cook S.A., Cowie M.R., Prasad S.K. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67:2996–3010. - PubMed
    1. Garcia-Pavia P., Cobo-Marcos M., Guzzo-Merello G. Genetics in dilated cardiomyopathy. Biomark Med. 2013;7:517–533. - PubMed
    1. Cuenca S., Ruiz-Cano M.J., Gimeno-Blanes J.R. Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant. 2016;35:625–635. - PubMed
    1. Michels V.V., Moll P.P., Miller F.A. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77–82. - PubMed
    1. Burkett E.L., Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45:969–981. - PubMed

Publication types

Substances